|
Ceralasertib Clinical Trials
9 actively recruiting trials across 5 locations
Also known as: ATR Kinase Inhibitor AZD6738, AZD-6738, AZD6738
Pipeline
Phase 1: 2Phase 2: 6Phase 1/2: 1
Top Sponsors
- University of Leeds1
- SWOG Cancer Research Network1
- Rahul Aggarwal1
- National Cancer Institute (NCI)1
- Muhammad Furqan1
Indications
- Cancer9
- Lung Cancer4
- Breast Cancer3
- Metastatic Breast Carcinoma2
- Anatomic Stage IV Breast Cancer AJCC v82
Other4 trials
Duarte, California1 trial
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
City of Hope Comprehensive Cancer Center
Phase 2
Irvine, California1 trial
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Phase 1
Newark, Delaware1 trial
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Helen F Graham Cancer Center
Phase 2
Chicago, Illinois1 trial
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
University of Illinois Medical Center
Phase 2
Houston, Texas1 trial
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
M D Anderson Cancer Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.